Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates.

Flynn BJ, Kastenmüller K, Wille-Reece U, Tomaras GD, Alam M, Lindsay RW, Salazar AM, Perdiguero B, Gomez CE, Wagner R, Esteban M, Park CG, Trumpfheller C, Keler T, Pantaleo G, Steinman RM, Seder R.

Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7131-6. doi: 10.1073/pnas.1103869108. Epub 2011 Apr 5.

2.

HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.

García-Arriaza J, Perdiguero B, Heeney JL, Seaman MS, Montefiori DC, Yates NL, Tomaras GD, Ferrari G, Foulds KE, Roederer M, Self SG, Borate B, Gottardo R, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo AD, Weiss DE, Lee C, Kibler KV, Jacobs BL, Wagner R, Ding S, Pantaleo G, Esteban M.

J Virol. 2017 Apr 13;91(9). pii: e02182-16. doi: 10.1128/JVI.02182-16. Print 2017 May 1.

3.

Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses.

Zurawski G, Shen X, Zurawski S, Tomaras GD, Montefiori DC, Roederer M, Ferrari G, Lacabaratz C, Klucar P, Wang Z, Foulds KE, Kao SF, Yu X, Sato A, Yates NL, LaBranche C, Stanfield-Oakley S, Kibler K, Jacobs B, Salazar A, Self S, Fulp W, Gottardo R, Galmin L, Weiss D, Cristillo A, Pantaleo G, Levy Y.

J Virol. 2017 Apr 13;91(9). pii: e01596-16. doi: 10.1128/JVI.01596-16. Print 2017 May 1.

4.

Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A.

Idoyaga J, Lubkin A, Fiorese C, Lahoud MH, Caminschi I, Huang Y, Rodriguez A, Clausen BE, Park CG, Trumpfheller C, Steinman RM.

Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2384-9. doi: 10.1073/pnas.1019547108. Epub 2011 Jan 24.

5.

Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacy.

Jackson RJ, Worley M, Trivedi S, Ranasinghe C.

Vaccine. 2014 Sep 29;32(43):5703-14. doi: 10.1016/j.vaccine.2014.08.023. Epub 2014 Aug 20.

6.

Loading dendritic cells with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses.

Climent N, Munier S, Piqué N, García F, Pavot V, Primard C, Casanova V, Gatell JM, Verrier B, Gallart T.

Vaccine. 2014 Oct 29;32(47):6266-76. doi: 10.1016/j.vaccine.2014.09.010. Epub 2014 Sep 19.

PMID:
25240755
7.

Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses.

Tritel M, Stoddard AM, Flynn BJ, Darrah PA, Wu CY, Wille U, Shah JA, Huang Y, Xu L, Betts MR, Nabel GJ, Seder RA.

J Immunol. 2003 Sep 1;171(5):2538-47.

8.

Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.

Perdiguero B, Gómez CE, Cepeda V, Sánchez-Sampedro L, García-Arriaza J, Mejías-Pérez E, Jiménez V, Sánchez C, Sorzano CÓ, Oliveros JC, Delaloye J, Roger T, Calandra T, Asbach B, Wagner R, Kibler KV, Jacobs BL, Pantaleo G, Esteban M.

J Virol. 2015 Jan 15;89(2):970-88. doi: 10.1128/JVI.02469-14. Epub 2014 Oct 29.

9.

Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.

Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, Tang A, Chen M, Huang L, Harris V, Freed DC, Wilson KA, Dubey S, Zhu DM, Nawrocki D, Mach H, Troutman R, Isopi L, Williams D, Hurni W, Xu Z, Smith JG, Wang S, Liu X, Guan L, Long R, Trigona W, Heidecker GJ, Perry HC, Persaud N, Toner TJ, Su Q, Liang X, Youil R, Chastain M, Bett AJ, Volkin DB, Emini EA, Shiver JW.

J Virol. 2003 Jun;77(11):6305-13.

10.

Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine.

Trumpfheller C, Finke JS, López CB, Moran TM, Moltedo B, Soares H, Huang Y, Schlesinger SJ, Park CG, Nussenzweig MC, Granelli-Piperno A, Steinman RM.

J Exp Med. 2006 Mar 20;203(3):607-17. Epub 2006 Feb 27.

12.

A dendritic cell targeted vaccine induces long-term HIV-specific immunity within the gastrointestinal tract.

Ruane D, Do Y, Brane L, Garg A, Bozzacco L, Kraus T, Caskey M, Salazar A, Trumpheller C, Mehandru S.

Mucosal Immunol. 2016 Sep;9(5):1340-52. doi: 10.1038/mi.2015.133. Epub 2016 Jan 6.

PMID:
26732678
13.

Development of a DNA-MVA/HIVA vaccine for Kenya.

Hanke T, McMichael AJ, Mwau M, Wee EG, Ceberej I, Patel S, Sutton J, Tomlinson M, Samuel RV.

Vaccine. 2002 May 6;20(15):1995-8. Review.

PMID:
11983261
14.

Liposome-encapsulated HIV-1 Gag p24 containing lipid A induces effector CD4+ T-cells, memory CD8+ T-cells, and pro-inflammatory cytokines.

Steers NJ, Peachman KK, McClain S, Alving CR, Rao M.

Vaccine. 2009 Nov 16;27(49):6939-49. doi: 10.1016/j.vaccine.2009.08.105. Epub 2009 Sep 11.

PMID:
19748578
15.

Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.

Garber DA, O'Mara LA, Zhao J, Gangadhara S, An I, Feinberg MB.

PLoS One. 2009;4(5):e5445. doi: 10.1371/journal.pone.0005445. Epub 2009 May 6.

16.

Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.

Kanagavelu SK, Snarsky V, Termini JM, Gupta S, Barzee S, Wright JA, Khan WN, Kornbluth RS, Stone GW.

Vaccine. 2012 Jan 17;30(4):691-702. doi: 10.1016/j.vaccine.2011.11.088. Epub 2011 Dec 4.

17.

Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.

Chege GK, Burgers WA, Stutz H, Meyers AE, Chapman R, Kiravu A, Bunjun R, Shephard EG, Jacobs WR Jr, Rybicki EP, Williamson AL.

J Virol. 2013 May;87(9):5151-60. doi: 10.1128/JVI.03178-12. Epub 2013 Feb 28.

18.
19.
20.

Mucosal and systemic anti-GAG immunity induced by neonatal immunization with HIV LAMP/gag DNA vaccine in mice.

Goldoni AL, Maciel M Jr, Rigato PO, Piubelli O, de Brito CA, Melo A, Marques ET, August JT, Duarte AJ, Sato MN.

Immunobiology. 2011 Apr;216(4):505-12. doi: 10.1016/j.imbio.2010.08.007. Epub 2010 Sep 25.

PMID:
20870310

Supplemental Content

Support Center